masitinib

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

Masitinib Plus Gemcitabine in Pancreatic Cancer

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence

Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid Arthritis

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis